Research Papers:

Identification of a circulating microRNA signature to distinguish recurrence in breast cancer patients

Dezheng Huo _, Wendy M. Clayton, Toshio F. Yoshimatsu, Jianjun Chen and Olufunmilayo I. Olopade

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:55231-55248. https://doi.org/10.18632/oncotarget.10485

Metrics: PDF 2034 views  |   HTML 3399 views  |   ?  


Dezheng Huo1, Wendy M. Clayton2, Toshio F. Yoshimatsu2, Jianjun Chen3, Olufunmilayo I. Olopade2

1Department of Public Health Sciences, University of Chicago, Chicago, IL, USA

2Section of Hematology and Oncology, Department of Medicine, University of Chicago, Chicago, IL, USA

3Department of Cancer Biology, University of Cincinnati, Cincinnati, OH, USA

Correspondence to:

Dezheng Huo, email: dhuo@health.bsd.uchicago.edu

Keywords: MicroRNAs, breast neoplasms, prognosis, serum, real-time polymerase chain reaction

Received: December 31, 2015    Accepted: May 12, 2016    Published: July 08, 2016


There is an urgent need for novel noninvasive prognostic biomarkers for monitoring the recurrence of breast cancer. The purpose of this study is to identify circulating microRNAs that can predict breast cancer recurrence. We conducted a microRNA profiling experiment in serum samples from 48 breast cancer patients using Exiqon miRCURY microRNA RT-PCR panels. Significantly differentiated miRNAs for recurrence in the discovery profiling were further validated in an independent set of sera from 20 patients with breast cancer recurrences and 22 patients without recurrences. We identified seven miRNAs that were differentially expressed between breast cancer patients with and without recurrences, including four miRNAs upregulated (miR-21-5p, miR-375, miR-205-5p, and miR-194-5p) and three miRNAs downregulated (miR-382-5p, miR-376c-3p, and miR-411-5p) for recurrent patients. Using penalized logistic regression, we built a 7-miRNA signature for breast cancer recurrence, which had an excellent discriminating capacity (concordance index=0.914). This signature was significantly associated with recurrence after adjusting for known prognostic factors, and it was applicable to both hormone-receptor positive (concordance index=0.890) and triple-negative breast cancers (concordance index=0.942). We also found the 7-miRNA signature were reliably measured across different runs of PCR experiments (intra-class correlation coefficient=0.780) and the signature was significantly higher in breast cancer patients with recurrence than healthy controls (p=1.1x10-5). In conclusion, circulating miRNAs are promising biomarkers and the signature may be developed into a minimally invasive multi-marker blood test for continuously monitoring the recurrence of breast cancer. It should be further validated for different subtypes of breast cancers in longitudinal studies.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 10485